ESOC 2026 | HOPE trial: hemodynamic optimization of cerebral perfusion after successful EVT in AIS
Pol Camps-Renom, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, discusses the results of HOPE (NCT04892511), a randomized trial on hemodynamic optimization of cerebral perfusion after successful endovascular therapy (EVT) in patients with acute ischemic stroke (AIS). Dr Camps-Renom highlights that the trial found a significant improvement in functional outcomes at 90 days, meeting its primary endpoint. This interview took place at the 12th European Stroke Organisation Conference (ESOC) in Maastricht, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, this was named the HOPE trial and the HOPE trial was a multi-centre prospective randomized trial with open label and blinded endpoint that was conducted at 11 stroke centers in Spain from 2021 to 2025. And the main aim of the trial was to test the hypothesis that the reperfusion guided systolic blood pressure targeted strategy might lead to improved functional outcomes in patients after EVT compared to current clinical guideline recommendations...
Yeah, this was named the HOPE trial and the HOPE trial was a multi-centre prospective randomized trial with open label and blinded endpoint that was conducted at 11 stroke centers in Spain from 2021 to 2025. And the main aim of the trial was to test the hypothesis that the reperfusion guided systolic blood pressure targeted strategy might lead to improved functional outcomes in patients after EVT compared to current clinical guideline recommendations. And so what we did in the trial was to randomize patients who achieved a successful reperfusion after EVT, rather to be allocated to the control arm that these patients were treated according to current guidelines, or if they were allocated to the intervention group, they were stratified. The systolic BP target ranges were stratified according to the final reperfusion achieved. That was that patients with an incomplete reperfusion with an mTICI 2B had to be in a systolic blood pressure target range between 140 and 160. And patients with a final mTICI 2C/3 after the procedure had to be in a systolic blood pressure target range between 100 and 140. And this was applied over a treatment period of 72 hours and then we assessed functional outcome at 90 days. And so what we found the primary efficacy outcome set for the trial was the proportion of patients achieving favorable outcome at 90 days defined as a score of 0 to 2 in the modified Rankin scale and what we found is under the control trial group we found 46.7 percent of patients achieving favorable functional outcome and this proportion was greater in the intervention group with a 60.0% of patients and that was an absolute risk difference towards a benefit of 13% and an odds ratio of 1.71 towards a favorable outcome with intervention and all these efficacy analyses were statistically significant so the trial turned out to be a positive trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
